Announcements Trials
Browse Landscape

Phase

Phase 3 4

Status

Completed 2Active not recruiting 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 2Tuberous Sclerosis Complex-associated Refractory Seizures 1Kidney Neoplasms 1Graft vs Host Disease 1Bronchiolitis Obliterans Syndrome 1

Interventions

pembrolizumab 45Carboplatin 40Cisplatin 36Paclitaxel 29Pemetrexed 24Nivolumab 24Gemcitabine 23Dexamethasone 21Rituximab 18Ipilimumab 16Cyclophosphamide 15Fluorouracil 14Capecitabine 14atezolizumab 13Docetaxel 13trastuzumab deruxtecan 12durvalumab 12Trastuzumab 12Lenalidomide 12daratumumab 11Cytarabine 11olaparib 10Prednisone 10Bortezomib 10Bevacizumab 10130-nm albumin-bound paclitaxel 10Doxorubicin 9venetoclax 8Oxaliplatin 8Crizotinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Has announcements × Everolimus × Clear all
NCT04195750 2026-05-14

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
755 enrolled 28 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02811861 2026-02-23

CLEAR

Eisai Inc.

Phase 3 Active not recruiting
1,069 enrolled 12 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Incyte Corporation

Phase 3 Completed
330 enrolled 32 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT01713946 2018-11-07

EXIST-3

Novartis

Phase 3 Completed
366 enrolled 38 charts 1 FDA

Tuberous Sclerosis Complex-associated Refractory Seizures

Data powered by HemOnc (CC BY 4.0) Colophon âš¡